Get the Stockscreener App
0.779
2.63%
-0.021
After Hours:
.78
0.001
+0.13%
Kronos Bio Inc stock is traded at $0.779, with a volume of 295.00K.
It is down -2.63% in the last 24 hours and down -18.00% over the past month.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
See More
Previous Close:
$0.80
Open:
$0.78
24h Volume:
295.00K
Relative Volume:
1.55
Market Cap:
$48.78M
Revenue:
-
Net Income/Loss:
$-112.67M
P/E Ratio:
-0.3995
EPS:
-1.95
Net Cash Flow:
$-79.26M
1W Performance:
-5.58%
1M Performance:
-18.00%
6M Performance:
-21.54%
1Y Performance:
-35.08%
1-Day Range:
$0.771
$0.825
1-Week Range:
$0.771
$0.8862
52-Week Range:
$0.69
$1.60
Kronos Bio Inc Stock (KRON) Company Profile
Name
Kronos Bio Inc
Sector
Industry
Phone
(650) 781-5200
Address
1300 S. EL CAMINO REAL, SAN MATEO
Compare KRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.779 | 48.78M | 0 | -112.67M | -79.26M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-14-24 | Downgrade | TD Cowen | Buy → Hold |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jun-24-21 | Initiated | H.C. Wainwright | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Goldman | Buy |
| Nov-03-20 | Initiated | Jefferies | Buy |
| Nov-03-20 | Initiated | Piper Sandler | Overweight |
View All
Kronos Bio Inc Stock (KRON) Latest News
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Kronos Bio Reports 2024 Financial Results - TipRanks
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023) - Yahoo Finance
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Kronos Bio earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
Kronos Bio, Inc. SEC 10-K Report - TradingView
China Revives Its Carbon Credit Market: Price Swings & Future Outlook - The Globe and Mail
Navigating the U.S. Planting Season with Enhanced Risk Management - The Globe and Mail
Shootin' the Bull about cattle feeders - The Globe and Mail
KRONOS BIO Earnings Preview: Recent $KRON Insider Trading, Hedge Fund Activity, and More - Nasdaq
Kronos Bio (KRON) to Release Quarterly Earnings on Thursday - Defense World
Kronos Bio Insider Ups Holding By 36% During Year - Yahoo Finance
Kronos Bio, Inc. (NASDAQ:KRON) Shares Sold by Partners Capital Investment Group LLP - MarketBeat
Peapod Lane Capital LLC Purchases New Position in Kronos Bio, Inc. (NASDAQ:KRON) - MarketBeat
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up - MSN
Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Increases By 16.5% - MarketBeat
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully - Yahoo Finance
Analyzing Kronos Bio (NASDAQ:KRON) and Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8% – Here’s What Happened - Defense World
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8%Should You Sell? - MarketBeat
Kronos Bio ends partnership with Genentech By Investing.com - Investing.com Australia
Kronos Bio ends partnership with Genentech - Investing.com India
Kronos Bio Ends Collaboration with Genentech and Roche - TipRanks
Kronos Bio (NASDAQ:KRON) Trading 8.5% HigherHere's Why - MarketBeat
Struggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staff - SFGATE
Biotech with Cambridge lab slashes 83% of staff, CEO departs - NBC Boston
Kronos Bio Inc Stock (KRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):